Skip to main navigation
Skip to search
Skip to main content
HSC Home
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Search by expertise, name or affiliation
Targeted molecular therapeutic options for hepatocellular carcinoma
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Targeted molecular therapeutic options for hepatocellular carcinoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Advanced Hepatocellular Carcinoma
25%
Cancer Causes
25%
Cancer Mortality
25%
Chemotherapy
25%
Clinical Trials
25%
Conventional Chemotherapy
25%
Growth Factor Signaling Pathways
25%
Growth Signaling
25%
Hepatitis
25%
Hepatocellular Carcinoma
100%
Hepatocellular Carcinoma Patients
50%
Kinase Inhibitor
25%
Lenvatinib
25%
Liver Cancer
100%
Major Risk Factors
25%
Metabolic Conditions
25%
Mode of Action
25%
Molecular Therapeutics
100%
Most Common Form
25%
Obesity
25%
Sorafenib
25%
Targeted Molecular Therapy
50%
Targeted Therapy
25%
Therapeutic Agents
25%
Therapeutic Potential
100%
Tyrosine Kinase
25%
Medicine and Dentistry
Chemotherapy
40%
Clinical Trial
20%
Growth Factor
20%
Hepatocellular Carcinoma
100%
Infection
20%
Lenvatinib
20%
Liver Cancer
80%
Malignant Neoplasm
20%
Mediator
20%
Molecularly Targeted Therapy
40%
Phosphotransferase Inhibitor
20%
Protein Tyrosine Kinase
20%
Side Effect
20%
Signal Transduction
20%
Sorafenib
20%
Targeted Therapy
20%
Therapeutic Agent
20%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
40%
Clinical Trial
20%
Growth Factor
20%
Infection
20%
Lenvatinib
20%
Liver Cancer
80%
Liver Cell Carcinoma
100%
Malignant Neoplasm
20%
Phosphotransferase Inhibitor
20%
Protein Tyrosine Kinase
20%
Side Effect
20%
Sorafenib
20%